Medicines360

What Medicines360 does

Medicines360 is a San Francisco-based nonprofit pharmaceutical organization founded in 2009 that develops and commercializes women's health products, with a core focus on hormonal intrauterine devices. The company manufactures a levonorgestrel-releasing 52 mg IUD system sold as Liletta in the United States through commercial partner AbbVie and as Avibela in low- and middle-income countries across Africa, South and Southeast Asia, Central America, and the Caribbean via a wholly-owned subsidiary (Impact RH360) and distribution partners including DKT WomanCare and Pharma Dynamics. Both products are approved for long-acting reversible contraception (up to 8 years) and treatment of heavy menstrual bleeding, with more than 1.8 million US women served and 65,000+ units supplied globally since 2019.

The organization operates its 360 Innovation Hub, a development platform that identifies gaps in women's health and moves products from concept through regulatory approval to commercialization, with a women-centric design approach and access planning from day one. Beyond the hormonal IUD franchise, Medicines360 has expanded into maternal health through three in-licensed programs: the PeriPeach investigational device for obstetric anal sphincter injury prevention, blood-based biomarkers from the University of Cambridge for fetal growth restriction, gestational diabetes, and preeclampsia risk prediction, and non-invasive retinal imaging from the University of Edinburgh for pregnancy-related cardiovascular and metabolic risk assessment, with Wellcome Leap as a co-development partner.

Medicines360 funds its mission through a hybrid nonprofit model combining commercial product sales and licensing royalties (AbbVie channel and global distribution), philanthropic donations, government grants, and strategic partnerships. The organization holds 4,000 US safety net clinic relationships and is registered to sell Avibela in 13 countries with a pipeline targeting 88 markets, with the company reporting $120 million in estimated savings to the US public healthcare system through its Liletta access program.

Name

Medicines360

Legal name

Medicines360

Website

https://medicines360.org

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Medicines360 is a nonprofit pharmaceutical organization that develops and distributes hormonal IUDs and maternal health products, serving underserved women in the US via AbbVie and in low- and middle-income countries through subsidiary Impact RH360 and global distribution partners.

Ownership category

akta.pro rank

Product category

Women's Reproductive Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN), Prenatal, Newborn & Reproductive Diagnostics (NIPT, IVF/PGT, newborn screening) (HLAAALAJ)

Keywords

• Women's health pharmaceuticals
• Hormonal IUD products
• Reproductive health devices
• Maternal health innovations
• Nonprofit pharmaceutical organization

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Others

Revenue model

1. Product Sales and Licensing Royalties: Medicines360 generates revenue through product sales and licensing royalties from Liletta (US commercial partner AbbVie) and Avibela (global distribution partners). As a nonprofit, revenues are reinvested into advancing women's health innovations.
2. Donor Support and Philanthropy: Diverse funding from private foundations, government grants, and individual donors enables the organization to pursue bold ideas and develop health innovations addressing important health challenges faced by women.
3. Strategic Partnerships: Partnerships with industry leaders provide funding and resources while enabling product commercialization and access expansion.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Core offering

Medicines360 develops, manufactures, and distributes women's health pharmaceutical products, principally a levonorgestrel 52mg hormonal intrauterine system (IUD) marketed as Liletta® in the United States (via commercial partner AbbVie) and Avibela™ in low- and middle-income countries. The same IUD product is approved for long-acting reversible contraception (up to 6-8 years) and treatment of heavy menstrual bleeding. Through its 360 Innovation Hub, the organization also incubates and licenses new maternal health technologies including biomarker and retinal imaging diagnostics for stillbirth risk prediction.

Product overview

Medicines360 is a nonprofit women's health innovation organization offering two branded hormonal intrauterine device (IUD) products: Liletta® for the U.S. market and Avibela™ for low- and middle-income countries. Both products are the same levonorgestrel 52 mg intrauterine system providing long-acting reversible contraception (LARC) and treatment of heavy menstrual bleeding. The organization operates through its 360 Innovation Hub to develop and expand access to women's health products globally.

Differentiator

Problem solved

Functional benefit

Brands

• Liletta: Levonorgestrel-releasing Intrauterine System (IUD) 52mg available in the United States through commercial partner AbbVie. Approved for contraception for up to eight years and treatment of heavy menstrual bleeding.
• Avibela
• 360 Innovation Hub
• M360 ASPIRE Program

Products and services

• Liletta® A levonorgestrel-releasing intrauterine system (IUS/IUD) 52 mg providing long-acting reversible contraception for up to eight years and treatment of heavy menstrual bleeding. Available in the United States through commercial partner AbbVie for women in healthcare and contraceptive deserts.
• Avibela™ A levonorgestrel-releasing intrauterine system (IUS/IUD) 52 mg providing long-acting reversible contraception and treatment of heavy menstrual bleeding for up to six to eight years. Available in Africa, South and Southeast Asia, Central America, and the Caribbean through Medicines360's subsidiary Impact RH360 and distribution partners (DKT WomanCare, Pharma Dynamics), offered at the lowest price ever for a hormonal IUD.

Quantifiable outcome

• Over 1.8 million women served with hormonal IUDs in the US
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Pharma DynamicscoreChannel Partner/ Reseller/ Distributor · 1 April 2026Partnership for launch of AVIBELA in South Africa, marking the country's first generic levonorgestrel 52 mg intrauterine device for long-acting reversible contraception and treatment of heavy menstrual bleeding.
• Wellcome LeapcoreStrategic or Co-development Partner · 12 January 2026Collaboration to accelerate development and access to pregnancy and stillbirth risk-reduction tools including blood biomarker-based tests and non-invasive retinal imaging technologies. Partnership aims to translate Wellcome Leap's In Utero program discoveries into commercial products.
• University of CambridgecoreOEM/ Whitelabel/ Licensing Partner · 1 January 2026Licensed global rights to new blood-based biomarker discoveries that could identify risk of fetal growth restriction, gestational diabetes mellitus, and preeclampsia - conditions associated with stillbirth.
• University of EdinburghcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2026Licensed global rights to non-invasive retinal eye imaging technology designed to detect cardiovascular and metabolic changes during pregnancy for stillbirth risk assessment.
• Fruits of Labor, Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 September 2025Acquired global licensing rights to PeriPeach, an investigational medical device designed to prevent obstetric anal sphincter injuries (OASIS) during vaginal birth, invented by Dr. Tess Kim.
• DKT WomanCare GlobalcoreChannel Partner/ Reseller/ Distributor · 1 January 2024Strategic partnership to expand access to AVIBELA, the affordable hormonal IUD, across Africa, South and Southeast Asia, Central America, and the Caribbean. DKT WomanCare leverages its global marketing expertise and network of partnerships with ministries of health, global procurement agencies, and distributors.
• AbbViecoreChannel Partner/ Reseller/ DistributorCommercial partner for Liletta (levonorgestrel-releasing intrauterine system 52mg) availability in the United States.
• Direct ReliefminorStrategic or Co-development PartnerPartner organization working to improve health outcomes, listed among Medicines360's partnership ecosystem.
• NaariminorStrategic or Co-development PartnerPartner organization in women's health space, listed among Medicines360's partnership ecosystem.
• Wellcome LeapcoreStrategic or Co-development PartnerGlobal health organization partner, logo displayed on Medicines360 website. Wellcome Leap is a nonprofit building and executing breakthrough programs in human health.
• Bay Area Global Health AllianceminorStrategic or Co-development PartnerAlliance member dedicated to improving access to care, listed among Medicines360's alliance memberships.
• Impact RH360coreOthersMedicines360's wholly owned subsidiary that offers AVIBELA at affordable prices in Africa, South and Southeast Asia, Central America, and the Caribbean.

Scale indicators9 records

Recent moves9 records

Expansion highlights6 records

Others

• Civica Rx: A US nonprofit pharmaceutical organization (cited alongside Medicines360 in the GAO report) using a nonprofit model to improve drug access, comparable on business model rather than therapeutic area.

Emerging players

• Agile Therapeutics: A women's-healthcare company commercializing the Twirla contraceptive patch, comparable as a contraception-focused product developer targeting similar end users.
• Daré Bioscience: A clinical-stage company developing innovative women's reproductive-health and contraception products, comparable to Medicines360's pipeline-driven women's-health innovation model.
• Evofem Biosciences: Develops and commercializes women's contraception and sexual-health products (Phexxi), overlapping with Medicines360's contraceptive product focus.

Regional players

• Mithra Pharmaceuticals: A Belgium-based women's-health company developing contraceptives and reproductive-health products, comparable in category but primarily European in focus.

Broad incumbents

• Bayer (Women's Health): Maker of the Mirena, Kyleena and Skyla hormonal IUD franchise, Bayer is the dominant incumbent competing directly in the same levonorgestrel-IUD category as Liletta/Avibela.
• Organon: A women's-health-focused pharmaceutical spinout with contraceptive and reproductive-health products, overlapping broadly with Medicines360's women's-health product focus.

Direct peers

• CooperSurgical: Markets the Paragard IUD and a broad women's-health/contraception device portfolio, competing in the same long-acting reversible contraception market as Medicines360's IUDs.
• DKT International: A nonprofit focused on affordable contraception and reproductive-health products across low- and middle-income countries; its DKT WomanCare arm is both a partner and a directly comparable access-driven distributor of family-planning products.
• Population Council: A nonprofit research organization that develops contraceptive technologies (e.g., the Annovera ring and IUDs) for global reproductive health, directly mirroring Medicines360's nonprofit women's-health product development and access mission.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medicines360
• Xx.com/Medicines360

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicines360